

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

A. Thomas LOOK et al.

Serial No. 10/659,705

Filed: September 11, 2003



: Attn: Office of Initial  
: Patent Examination

: Group Art Unit: 1632

For: TRANSGENIC CANCER MODELS IN FISH

REQUEST FOR CORRECTED FILING RECEIPT

Honorable Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

Attached is a copy of the Filing Receipt received from the U.S. Patent and Trademark Office in the above-referenced application. The city of residence for the second inventor is incorrect in the Filing Receipt. Also attached is a copy of the Declaration and Power of Attorney (filed February 24, 2004) and an Updated Application Data Sheet listing the correct city of residence for this inventor. Please correct this information as indicated in red on the attached copy of the Filing Receipt. It is requested that a corrected filing receipt be issued.

Since the error was made by the U.S. Patent and Trademark Office, it is believed that no fee is required with regard to this Request; however, in the event that a fee is required, the Commissioner is authorized to charge such fee to Deposit Account No. 08-0219. A duplicate copy of this letter is attached.

Respectfully submitted,

HALE AND DORR LLP


Tamera M. Pertmer, Ph.D.  
Agent for Applicant  
Registration No. 47,856

1455 Pennsylvania Avenue, NW  
Washington, D.C. 20004  
TEL: 202.942.8400  
FAX: 202.942.8484  
Date: 13 Apr 2004



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov



APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/659,705	09/11/2003	1632	1108	112706.123US2	24	74	7

24395  
HALE & DORR LLP  
THE WILLARD OFFICE BUILDING  
1455 PENNSYLVANIA AVE, NW  
WASHINGTON, DC 20004

CONFIRMATION NO. 6046  
UPDATED FILING RECEIPT



\*OC000000012065625\*

Date Mailed: 03/10/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

A. Thomas Look, North Reading, MA;  
David M. Langenau, ~~Boston~~, MA;  
Brookline

**Assignment For Published Patent Application**

Dana-Farber Cancer Institute, Boston, MA;

**Domestic Priority data as claimed by applicant**

This appln claims benefit of 60/409,585 09/11/2002

**Foreign Applications**

If Required, Foreign Filing License Granted: 12/24/2003

Projected Publication Date: 06/17/2004

Non-Publication Request: No

Early Publication Request: No

**\*\* SMALL ENTITY \*\***

Title

HALE AND DORR LLP Wash, DC

Base Date: 112706.123 US2

Filing Date: \_\_\_\_\_

Priority Date: \_\_\_\_\_

Filing Date: \_\_\_\_\_

Ext. \_\_\_\_\_ Dktd By UC

**Preliminary Class**

800

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).